Beta Bionics Stock

betabionics.comHealthcareFounded: 2015Funding to Date: $132MM

Beta Bionics is the developer of iLet, a revolutionary bionic pancreas that is driven by mathematical dosing algorithms, which incorporate lifelong autonomous learning to automatically control glycemia.

Register for Details

For more details on financing and valuation for Beta Bionics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Edward Damiano
Founder, President & Chief Executive Officer
Firas El-Khatib Ph.D
Co-Founder & Vice President, Autonomous Systems
Toby Milgrome
Co-Founder
Serafina Raskin
Vice President, Corporate Secretary & General Counsel
Edward Raskin
Vice President, Public Benefit Development and Corporate Strategy & Board Member

Board Members

Christian Foged
Novo Nordisk
Deirdre Ibsen
Edward Raskin
Jeffrey Hitchcock

Other companies like Beta Bionics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$2.51B
Sector
Last Round Est. Valuation
$453MM
Sector
Last Round Est. Valuation
$1.65B
Sector
Last Round Est. Valuation
$173MM
Sector
Last Round Est. Valuation
$368.08MM
Sector
Last Round Est. Valuation
$1.4B
Sector
Last Round Est. Valuation
$210.75MM
Sector
Last Round Est. Valuation
$265.75MM

News

The iLet is a pocket-sized, wearable investigational medical device that autonomously controls blood sugar in people with diabetes and other conditions --...
Boston-based Beta Bionics said this week that it closed a $63 million Series B round to support the development of its iLet bionic pancreas system for people with Type 1 diabetes. The company’s iLet device features an autonomous, dual-chamber infusion pump that is powered by dosing algorithms. Using machine learning and data from a continuous glucose monitor, […]